AbbVie (NYSE:ABBV) Stock Rating Upgraded by Erste Group Bank

AbbVie (NYSE:ABBV) was upgraded by analysts at Erste Group Bank from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Marketbeat Ratings reports.

ABBV has been the topic of several other research reports. Guggenheim lifted their price objective on AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a report on Tuesday. HSBC reaffirmed a “buy” rating and issued a $300.00 target price on shares of AbbVie in a research note on Monday, July 6th. Cantor Fitzgerald boosted their price objective on shares of AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research report on Monday. UBS Group raised their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Finally, Barclays increased their price objective on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $272.76.

AbbVie Stock Up 2.0%

Shares of ABBV stock traded up $4.81 during trading on Wednesday, hitting $248.61. The company had a trading volume of 931,752 shares, compared to its average volume of 7,007,513. AbbVie has a 52 week low of $190.75 and a 52 week high of $267.47. The stock has a market capitalization of $439.24 billion, a price-to-earnings ratio of 70.23, a price-to-earnings-growth ratio of 0.81 and a beta of 0.30. The stock’s 50-day moving average is $240.29 and its two-hundred day moving average is $224.41.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 466.39%. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the firm posted $2.97 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts predict that AbbVie will post 14.08 EPS for the current fiscal year.

Hedge Funds Weigh In On AbbVie

Large investors have recently made changes to their positions in the business. Norges Bank bought a new stake in AbbVie in the fourth quarter worth $5,865,055,000. Wellington Management Group LLP raised its position in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Capital World Investors boosted its stake in AbbVie by 106.3% in the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after purchasing an additional 6,736,161 shares in the last quarter. Cardano Risk Management B.V. grew its position in AbbVie by 914.6% during the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after purchasing an additional 4,908,260 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after purchasing an additional 4,190,487 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong second-quarter results: AbbVie reported revenue of $16.99 billion, up 10.2% year over year and ahead of expectations, while adjusted EPS of $3.65 exceeded the consensus estimate of $3.61. Growth in Skyrizi, Rinvoq and neuroscience products helped support higher 2026 revenue guidance. ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset
• Positive Sentiment: New Botox opportunity: The FDA accepted Allergan Aesthetics’ supplemental application to review BOTOX Cosmetic for masseter muscle prominence, commonly associated with jawline appearance. If approved, Botox would be the first neurotoxin indicated for this use in the United States, expanding AbbVie’s aesthetics franchise. AbbVie Wins FDA Review For BOTOX Cosmetic In Jawline Treatment Push
• Positive Sentiment: Positive analyst view: Cantor Fitzgerald raised its AbbVie price target to $285, while broader Wall Street commentary remains bullish. One forecast also maintains a buy view and expects additional upside despite the stock trading near its highs. Cantor Fitzgerald Boosts AbbVie Price Target to $285.00
• Positive Sentiment: Pipeline and market access progress: Canada’s drug agency recommended conditional public reimbursement for migraine drug Ubrelvy, potentially improving access. AbbVie is also advancing late-stage oncology research with ABBV-706, adding longer-term pipeline potential. UBRELVY Recommended for Reimbursement by Canada’s Drug Agency
• Neutral Sentiment: Apogee acquisition mixed: Baron Capital exited Apogee Therapeutics after AbbVie’s buyout. The transaction adds pipeline assets and could strengthen immunology, but management previously indicated that deal-related dilution and higher research spending would weigh on near-term EPS. Baron Capital Exits Apogee Therapeutics Following AbbVie Buyout
• Negative Sentiment: Valuation remains a concern: With a forward-looking valuation viewed as demanding and some models projecting a price below current levels, investors may question how much of AbbVie’s growth is already reflected in the stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.